Break the Pattern
of Obesity and Type 2 Diabetes
People struggling with obesity and type 2 diabetes are caught in a relentless cycle of disease progression that causes them to rely on countless prescriptions that simply put a bandage on their disease. Fractyl Health seeks to break this pattern by pursuing therapies that target root causes of obesity and type 2 diabetes. Our goal is to free humanity from these diseases and the unending pattern of drugs required to treat them.
Now recruiting for a clinical research study in obesity.
Targeting the root causes of serious metabolic diseases.
We target metabolic diseases like obesity and type 2 diabetes where they begin: the duodenum and pancreas. Our platforms offer patients the potential for long-term freedom from disease without long-term drug therapy.
Can you imagine a world without obesity and type 2 diabetes?
We can. By focusing on where metabolic disease begins: in the gut.
Advancing potential breakthroughs in targeted metabolic therapies.
Revita
An outpatient endoscopic procedure designed to resurface the lining of the duodenum—targeting a root cause of obesity.
Rejuva
A one-time gene therapy platform designed to enable the long-term remission of obesity and type 2 diabetes by targeting pancreatic islet cells.
Leaders. Experts. Innovators.
We are a mission-driven team united in our common goal: to break the current pattern of chronic medical treatment faced by too many patients with obesity and type 2 diabetes. Fractyl is pursuing breakthrough therapies—the type of therapies we would want for ourselves and our loved ones.
We trust our GUTS.
At Fractyl, we trust the science—and each other. We are united in our passion to develop breakthrough metabolic therapies that could prevent, reverse, and even put an end to these diseases once and for all.
Revita® is for investigational use only in the US under Federal law. We hereby disclaim any warranties or guarantees regarding the efficacy or safety of Revita®. While we strive for quality and reliability, individual results may vary. Users are encouraged to consult with healthcare professionals and assess personal suitability before using the device.
Rejuva® is in early development and not approved by any regulatory body for investigational or commercial use.